We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Incorporating AI Into Drug Discovery
Product News

Incorporating AI Into Drug Discovery

Incorporating AI Into Drug Discovery
Product News

Incorporating AI Into Drug Discovery


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Incorporating AI Into Drug Discovery"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Optibrium™, a developer of software for drug discovery has announced the introduction of its Augmented Chemistry™ services, which provide collaborators with novel artificial intelligence technologies to supplement their skills and experience, enabling them to make more effective decisions and advance their drug discovery projects.

Augmented Chemistry™ services are built on a unique deep learning capability for data imputation, Alchemite™, which has been developed in collaboration with Intellegens Limited. Alchemite™ learns simultaneously across all experimental endpoints in a project or corporate database, even based on limited data. The resulting model can automatically highlight the most confident, and therefore accurate, predictions on which to base experimental decisions, including the identification of new or previously overlooked high-quality compounds.


Advertisement